Compare GROV & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GROV | CTSO |
|---|---|---|
| Founded | 2016 | 1997 |
| Country | United States | United States |
| Employees | 415 | N/A |
| Industry | Package Goods/Cosmetics | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.4M | 45.7M |
| IPO Year | N/A | 2008 |
| Metric | GROV | CTSO |
|---|---|---|
| Price | $1.41 | $0.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $1.60 | ★ $5.38 |
| AVG Volume (30 Days) | 59.9K | ★ 62.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,503,908.00 |
| Revenue This Year | N/A | $7.29 |
| Revenue Next Year | $3.63 | $8.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 48.53 |
| 52 Week Low | $1.02 | $0.60 |
| 52 Week High | $1.72 | $1.39 |
| Indicator | GROV | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 44.07 | 71.89 |
| Support Level | $1.19 | $0.62 |
| Resistance Level | $1.46 | $0.85 |
| Average True Range (ATR) | 0.07 | 0.04 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 32.09 | 100.00 |
Grove Collaborative Holdings Inc is engaged in providing consumer products. It offers Cleaning accessories, Home and Pantry, Personal care products, Pets supplements and Other products. It is a sustainability oriented consumer products generator. It use connection with consumers to create and curate authentic, disruptive brands and products. Company builds natural products that perform as well as, many consumer packaged goods (CPG) brands (both conventional and natural), while being healthier for consumers and the planet.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.